Fiscal Q1 2025 revenue of $27.3 million, net income of $2.0 million, operating income of $4.0 million, and Adjusted EBITDA*…
Reports Net Revenues of $182.4 Million for the Three Months Ended June 30, 2024RANCHO CUCAMONGA, CA / ACCESSWIRE / August…
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial has enrolled over 50% of patients- Dermata continues…
JERSEY CITY, N.J. , Aug. 7, 2024 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report…
Discover the Advanced miniDxR Customizable Lateral Flow Reader and Comprehensive CDMO and CRO Services at Booth 30 CARLSBAD, Calif, Aug.…
Patient dosing has concluded for the second and last cohort of the pharmacokinetics study of AD04 Topline results expected during…
Survival analyses with CNM-Au8® 30 mg treatment compared to matched PRO-ACT controls demonstrated improved survival up to 3.5 years post-baselineCNM-Au8 treated…
Conference Call to Begin Today at 9:00 a.m. (ET)2Q 2024 Total revenues of $72M; +49% vs. 2Q 2023YTD 2024 Total…
SAN FRANCISCO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development…
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage…